Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).

Date publication

septembre 2019

Journal

Diabetes & metabolism

Auteurs

Membres identifiés du Cancéropôle Est :
Pr VERGES Bruno

Tous les auteurs :
Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31539622

Résumé

- SUSTAIN 10 compared the efficacy and safety of the anticipated most frequent semaglutide dose (1.0 mg) with the current most frequently prescribed liraglutide dose in Europe (1.2 mg), reflecting clinical practice.

Mots clés

Glucagon-like peptide-1 receptor agonist, Glycaemic control, Liraglutide, SUSTAIN, Semaglutide, Type 2 diabetes

Référence

Diabetes Metab.. 2019 Sep 10;: